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Introduction {#sec1}
============

Mitochondria are key organelles for cellular bioenergetics and constantly undergo dynamic remodeling processes, including fusion and fission to adjust to the cellular demand for energy. Mitochondrial dysfunction, impaired energy homeostasis, as well as an increased production of reactive oxygen species are associated to a variety of human disorders, including aging-associated diseases ([@bib6], [@bib34]) as well as kidney diseases (reviewed in [@bib35]). The contribution of mitochondrial dysfunction to disease onset or progression---either directly due to genetic mutations or indirectly as a consequence of an altered cellular homeostasis---remains unclear, especially in complex multi-causal disorders, such as diabetic nephropathy, the leading cause of end-stage renal disease (ESRD) in western countries. Therefore, understanding the functional role of mitochondria in the two essential compartments of the kidney, i.e., glomerulus and tubular system, is a crucial first step.

Mitochondria are the primary cellular source of ATP and essential for all eukaryotic cells ([@bib12]). They are highly dynamic structures that constantly divide and fuse to build an intracellular network that assures the distribution within the cell and is required to execute their pleiotropic activities, including among others aerobic ATP production, governing metabolic pathways, as well as apoptosis, participation in RNA and DNA production, and the biosynthesis of heme, certain amino acids, and lipids ([@bib24], [@bib36], [@bib45]). In addition, the inner mitochondrial membrane potential participates in the uptake of cytosolic Ca^2+^ and potentially serves as buffer for locally increased intracellular Ca^2+^ levels ([@bib50]). To this end, mitochondria maintained their ability for self-replication to face the metabolic energy demands of the cell. Adaptive mechanisms of the mitochondrial network operating energy metabolism and mitochondrial self-renewal are mitochondrial biogenesis and mitochondrial dynamics regulated by key molecules, including mitochondrial transcription factor A (TFAM), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), and dynamin-related protein 1 (DRP-1).

Primary mitochondriopathies mainly affect the CNS and skeletal muscle. In most cases, the renal involvement is limited to tubular dysfunction, comprising Fanconi or Bartter-like syndromes or renal tubular acidosis (reviewed in [@bib8]), reflecting the high ATP demand derived from mitochondrial OXPHOS necessary for electrolyte-transporting processes within the tubular apparatus. Only sporadically, mitochondriopathies are also linked to glomerular disease, in particular focal segmental glomerulosclerosis (FSGS) and steroid-resistant nephrotic syndrome (reviewed in [@bib35]). Moreover, another highly relevant clinical condition, i.e., acute kidney injury (AKI), emphasizes a different role of mitochondria in the two kidney compartments. AKI due to ischemia and reperfusion injury causes severe tubular dysfunction and, eventually, tubular necrosis and necroptosis (reviewed in [@bib25]), whereas the glomerular compartment remains functionally and morphologically intact. These findings cannot be simply explained by general differences in the cellular energy demand. As tubular function can be characterized as a highly energy-consuming process, so does the maintenance of the structural integrity of the glomerular filter.

The majority of kidney diseases evolve from the glomerulus, the renal filtration unit. The glomerular filter is composed of three anatomic layers: the fenestrated endothelial cell layer; the glomerular basement membrane (GBM); and the slit diaphragm between adjacent podocyte foot processes. Podocytes are pericyte-like epithelial cells that cover the outer aspect of the glomerular capillaries (reviewed in [@bib7]). The cells have to apply static forces to cope with the pulsating glomerular capillaries to maintain the glomerular filtration barrier. These include adaptive processes comprising actin-based cytoskeletal remodeling and hypertrophy to adjust for filtration demands. The critical function of these processes has been demonstrated in various podocyte-specific knockout approaches targeting hypertrophy and actin remodeling ([@bib18], [@bib44], [@bib58]), all leading to a uniform pathological sequel involving foot process effacement and detachment, and proteinuria is the most sensitive clinical parameter reflecting podocyte damage ([@bib11], [@bib39]).

In order to sustain the complex cellular morphology of interdigitating foot processes, podocytes rely on a constant energy supply and reservoir. It is so far not yet clear what kind of energy resources and pathways are mainly exploited under physiological conditions ([@bib1], [@bib33]). Moreover, there are conflicting results in glomerular disease concerning the role of mitochondria ([@bib13], [@bib21], [@bib22], [@bib26], [@bib56]), suggesting an unmet need to delineate the bioenergetic framework required to maintain the glomerular filter under physiological conditions and characterize the role of mitochondria in this unique functional compartment. Here, we applied an unbiased metabolomic approach to determine the podocytes' energy supply chain with special emphasis on the contribution of mitochondria. Therefore, we employed conditional *in vivo* targeting strategies specifically in podocytes to interfere with mitochondrial biogenesis by depleting *PPARGC1A* (later referred to as *Pgc-1α*), to inhibit mitochondrial fission by depleting *DNM1L* (later referred to as *Drp1*), and to diminish mtDNA copy number and transcription by deleting *Tfam*.

Results {#sec2}
=======

Podocytes Display Low Mitochondrial Density {#sec2.1}
-------------------------------------------

First, we performed transmission electron microscopy (TEM) to study the mitochondrial abundance and localization within glomerular podocytes. To this end, we analyzed 70 TEM pictures from 8 wild-type mice ([Figure 1](#fig1){ref-type="fig"}A). Podocytes showed a significantly lower mitochondrial density per cell area as compared to renal tubular cells (0.7 ± 0.7 versus 4.1 ± 1.6; p ≤ 0.001). Moreover, in podocytes, mitochondria were primarily found within the cytoplasm (71%) and primary processes (29%) but rarely seen within secondary processes. 3D-reconstructed glomeruli stained for the mitochondrial enzyme SOD2 (superoxide dismutase 2) and the glycolytic enzyme PKM2 (pyruvate kinase M2) confirmed the perinuclear localization of mitochondria ([Figure S1](#mmc1){ref-type="supplementary-material"}A), whereas PKM2 was found ubiquitously, suggesting podocyte processes as a large putative compartment of anaerobic glycolysis ([Figures S1](#mmc1){ref-type="supplementary-material"}B--S1D). Principal-component analysis (PCA) of metabolite content of glomeruli and the tubular compartment (obtained from 4 mice each) revealed a distinct metabolite pattern ([Figures 1](#fig1){ref-type="fig"}B and 1C), with high levels of amino acids (86%) and low levels of carbohydrates (12%) and lipids (1.4%) in glomeruli, although in the tubular compartment, carbohydrates were most abundant (carbohydrates 62%, amino acids 21%, and lipids 14%; [Figure 1](#fig1){ref-type="fig"}D). These observations of fundamental metabolic differences were also reflected by low levels of intermediates of the tricarboxylic acid cycle (TCA) found in glomeruli compared to the tubular compartment (7% versus 93%; [Figure 1](#fig1){ref-type="fig"}E).Figure 1Podocytes Display Low Mitochondrial Density(A) Image obtained by transmission electron microscopy (TEM) displaying a glomerulus with neighboring tubular cells. Boxed areas show details from a podocyte and a proximal tubular cell, respectively. Mitochondria are marked by arrowheads. The depicted image is stitched from a 3×3 array of single images. Quantification of mitochondrial density and distribution of mitochondria in podocytes (based on the analysis of 70 pictures obtained from 8 mice; ^∗∗∗^p ≤ 0.001; presented as mean ± SD).(B) Principal-component analysis (PCA) of metabolite content of glomeruli and the tubular compartment (obtained from 4 mice each).(C) Heatmap of metabolites detected in glomeruli and in the tubular compartment (obtained from 4 mice each).(D) Metabolite composition of glomerular and tubular samples based on superclasses of metabolites.(E) Abundance of intermediates of tricarboxylic acid (TCA) cycle in glomeruli and the tubular compartment.

Glycolysis and oxidative phosphorylation (OXPHOS) are the two major cellular pathways to produce energy. Most cells may switch between these pathways in order to cope with changing energy demands. Glycolysis reflects the conversion of glucose into pyruvate and, subsequently, into lactate in the cytoplasm (anaerobic glycolysis) or into CO~2~ and H~2~O within mitochondria (aerobic glycolysis). In addition, mitochondrial energy may also be derived from oxidation of fatty acids and glutamine. The podocytes' mitochondrial dependency on and flexibility for each of these energy sources can be determined by measuring the decline in oxygen consumption rate (OCR) upon addition of specific inhibitors (dependency % = \[baseline OCR − target inhibitor OCR/baseline OCR − all inhibitors OCR\] × 100; capacity % = (1 − \[baseline OCR − other 2 inhibitors OCR\]/\[baseline OCR − all inhibitors OCR\]) × 100). To gain further insights in the podocytes' energy sources under physiological conditions, we isolated primary podocytes from wild-type reporter mice ([Figure 2](#fig2){ref-type="fig"}A). First, we analyzed the mitochondrial contribution to the energy supply chain. Administration of etomoxir, an inhibitor of long fatty acid oxidation, resulted in a significant decrease in OCR, and inhibition of glutamine (by bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide \[BPTES\]) or pyruvate (by UK5099) oxidation resulted in marginal reductions of OCR only ([Figures 2](#fig2){ref-type="fig"}B--2D). These findings revealed that podocytes primarily utilize fatty acid oxidation and oxidation of glutamine or pyruvate is of minor importance ([Figures 2](#fig2){ref-type="fig"}C--2F). Next, we aimed to differentiate the podocytes' dependency on the anaerobic glycolysis and the activity of the respiratory chain. To this end, we measured the OCR of primary podocytes after administration of 2-deoxyglucose (2-DG), a glycolysis inhibitor competitively inhibiting the production of glucose-6-phosphate or vehicle followed by specific inhibitors (oligomycin, carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone \[FCCP\], and rotenone/antimycin A) of the respiratory chain ([Figure 2](#fig2){ref-type="fig"}G). The administration of 2-DG did not affect the OCR neither at baseline nor after addition of the OXPHOS inhibitors. We also measured the extracellular acidification rate (ECAR) to determine the release of protons into the supernatant as a result of the activity of the glycolysis pathway ([Figure 2](#fig2){ref-type="fig"}H). Podocytes showed a rapid glucose-induced increase in glycolytic activity with a maximal glycolytic capacity of 3.1 ± 0.5 mpH/min/1,000 cells after inhibition of the mitochondrial ATP production by addition of oligomycin. These findings were further substantiated by assessing the oxamate-sensitive ECAR rate ([Figures 2](#fig2){ref-type="fig"}I and 2J), confirming the observation that podocytes harbor a strong glycolytic activity. Last, we assessed the contribution of the distinct ATP-generating pathways to the overall ATP production in podocytes ([Figure 2](#fig2){ref-type="fig"}K). Although inhibition of the anaerobic glycolysis by administration of 2-DG or oxamate resulted in a significant decrease in the cellular ATP content, inhibition of O~2~-dependent pathways, including fatty acid oxidation, was of minor relevance. Taken together, low mitochondrial abundance, decreased levels of TCA intermediates, as well as a strong dependency on the anaerobic glycolysis support the hypothesis that podocytes do not primarily rely on mitochondrial energy resources under physiological conditions. To further substantiate this hypothesis, we explored phenotypes in three independent mouse models to interfere with mitochondrial function within podocytes specifically.Figure 2Primary Podocytes Rely on Glycolysis(A) Primary podocyte culture was obtained by crossing *hNPHS2Cre* mice with a *Tomato/EGFP* reporter strain. Schematic of glomerular culture followed by fluorescence-activated cell sorting (FACS) is shown.(B) Dependency and capacity of fatty acid oxidation obtained after etomoxir and BPTESm UK5099 injection or BPTES, UK5099 followed by etomoxir, respectively (mean ± SD). Final concentrations: etomoxir: 100 μM; BPTES: 30 μM; UK5099: 30 μM.(C) Dependency and capacity of glutamine oxidation obtained after BPTES and etomoxir, UK5099 or etomoxir, UK5099 followed by BPTES, respectively (mean ± SD). Final concentrations: etomoxir: 100 μM; BPTES: 30 μM; UK5099: 30 μM.(D) Dependency and capacity of pyruvate oxidation obtained after UK5099 and etomoxir, BPTES and etomoxir, BPTES followed by UK5099, respectively (mean ± SD). Final concentrations: etomoxir: 100 μM; BPTES: 30 μM; UK5099: 30 μM.(E) Statistics displaying substrate dependency of primary podocytes (data out of 3 experiments; ^∗^p ≤ 0.05; ^∗∗^p ≤ 0.01; mean ± SD).(F) Statistics displaying substrate capacity of primary podocytes (data out of 3 experiments; ^∗^p ≤ 0.05; ^∗∗^p ≤ 0.01; mean ± SD).(G) Oxygen consumption rate (OCR) of primary podocytes after injection of 2-deoxyglucose or vehicle followed by the inhibitors of the respiratory chain as indicated (mean ± SD). Final concentration: 2-DG: 50 mM; oligomycin: 1 μM; FCCP: 0.5 μM; rotenone: 0.5 μM; antimycin: 0.5 μM.(H) Extracellular acidification rate (ECAR) of primary podocytes obtained after injection of glucose or vehicle followed by oligomycin and 2-DG as indicated (mean ± SD). Final concentration: 2-DG: 50 mM; oligomycin: 1 μM; rotenone: 0.5 μM; antimycin: 0.5 μM.(I) ECAR of primary podocytes after oxamate or vehicle injection (mean ± SD). Final concentration: oxamate: 45 mM.(J) Statistics displaying ECAR after vehicle or oxamate injection (^∗∗∗^p ≤ 0.001; mean ± SD).(K) Statistics showing intracellular ATP content after 24-h treatment with 2-DG, oxamate, etomoxir, or oligomycin (^∗^p ≤ 0.05; ^∗∗^ p ≤ 0.01; mean ± SD). Final concentration: 2-DG: 50 mM; oxamate: 45 mM; etomoxir: 100 μM; oligomycin: 1 μM.

Podocytes Do Not Rely on Functional Mitochondrial Fission Machinery {#sec2.2}
-------------------------------------------------------------------

First, we evaluated the structural and functional consequences of a targeted deletion of *Drp1* and the inability to undergo mitochondrial fission in podocytes. We monitored knockout and respective wild-type animals for a period of 12 months. Within this time period, we did not observe significant differences in body weight gain or any increase in urinary albumin excretion, excluding podocyte dysfunction in *Drp1* podocyte knockout animals ([Figure 3](#fig3){ref-type="fig"}). Histological evaluation revealed no obvious morphological alterations up to 12 months of age ([Figure 3](#fig3){ref-type="fig"}H). Using TEM, we visualized the mitochondrial morphology in podocytes of 1-, 5-, and 7-month-old *Drp1*^*flox/flox*^*^∗^hNPHS2Cre* knockout and *Drp1*^*flox/flox*^ control mice. Although mitochondria in podocytes of 1-month-old knockout mice seemed to form a more distinctive tubular network, no other major abnormalities were detected ([Figures 4](#fig4){ref-type="fig"}A and 4B). At months 5 and 7, mitochondria of *Drp1* knockout mice appeared slightly swollen, probably reflecting the consequences of deficient mitochondrial division and accumulation of oxidative stress. However, even at these later time points, no signs of podocyte foot process effacement were detectable in *Drp1* knockout mice ([Figures 4](#fig4){ref-type="fig"}C--4F).Figure 3Loss of DRP1 Does Not Affect Glomerular Function and Morphology(A) Schematic illustrating targeted gene deletion approach of *Drp1* in podocytes using the Cre-loxP system.(B) Breeding strategy to generate a podocyte-based reporter strain. After isolation of GFP+ podocytes via FACS, DNA was prepared and respective genotypes were verified using the following primers: D1 (5′-CACTGAGAGCTCTATATGTAGGC-3′); D3 (5′-ACCAAAGTAAGGAATAGCTGTTG-3′); and D5 (5′-GAGTACCTAAAGTGGACAAGAGGTCC-3′). PCR products were detected at 315 bp and 539 bp.(C) Western blot analysis confirmed reduced DRP1 levels in glomeruli of conditional *Drp1*^*flox/flox*^*^∗^hNPHS2Cre* mice.(D) Densitometric quantification of DRP1 protein levels demonstrated a significant reduction in glomeruli derived from KO animals (n = 3; ^∗^p ≤ 0.05; mean ± SD).(E) Immunofluorescence stainings visualized absence of DRP1 in knockout podocytes. Dotted lines indicate the respective podocyte compartment, as marked with NEPHRIN staining.(F) 12-month follow-up period revealed no differences in body weight between wild-type and *Drp1* knockout animals (at least 3 animals per genotype and time point were analyzed; mean ± SD).(G) Measurement of ACR (albumin-to-creatinine ratio) revealed no differences during the 12-month follow-up period (at least 3 animals per genotype and time point were analyzed; mean ± SD).(H) Periodic acid Schiff (PAS)-stained kidney sections obtained from 1-month-old and 12-month-old *Drp1*^*flox/flox*^*^∗^hNPHS2Cre* mice and littermate controls showed normal glomerular structure.Figure 4Mitochondria Are Elongated in *Drp1*-Deficient PodocytesRepresentative TEM pictures displaying mitochondrial shape and density in podocytes. Sections were obtained from mouse kidneys at the age of 1 month, 5 months, and 7 months, respectively.

To further delineate the function of *Drp1* on podocyte metabolism, *in vivo* and *in vitro* mtDNA levels were quantified in isolated glomeruli obtained from 24-week-old mice with podocyte-specific deletion of *Drp1* and respective controls as a surrogate parameter of mitochondrial density. mtDNA was significantly reduced in mice lacking DRP1, as highlighted by reduced *Atp6* and *Cox1* abundance compared to *18 s* ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Functionally, gas chromatography-mass spectrometry (GC-MS) profiling from kidney cortex of respective mice revealed only minor differences on overall metabolite content and similar levels of lactate ([Figure S2](#mmc1){ref-type="supplementary-material"}B). To further elucidate the potential impact of *Drp1* depletion on podocyte metabolism, small interfering RNA (siRNA)-based knockdown approaches were performed with subsequent metabolic profiling. Using this approach, cellular DRP1 content significantly decreased ([Figure S2](#mmc1){ref-type="supplementary-material"}C); however, mitochondrial function and glycolysis as well as glycolytic capacity remained unaffected ([Figures S2](#mmc1){ref-type="supplementary-material"}D--S2G). Maximal respiratory capacity as assessed after FCCP exposure was even increased compared to siScrambled controls, suggesting a role of DRP1 in mitochondrial stress response ([Figure S2](#mmc1){ref-type="supplementary-material"}E). Assessment of the main mitochondrial fuel confirmed fatty acids a key source of podocyte OXPHOS. Knockdown of *Drp1*, however, did not affect mitochondrial fuel preference ([Figures S2](#mmc1){ref-type="supplementary-material"}H--S2O). In summary, *Drp1* deletion impacted the expression of certain mitochondria-encoded genes; however, further functional effects were not detectable.

Mitochondrial Biogenesis Is Dispensable for Podocyte Function {#sec2.3}
-------------------------------------------------------------

Next, we interfered with mitochondrial biogenesis and deleted *Pgc-1α* in podocytes specifically. We monitored *Pgc-1α* knockout and respective wild-type animals for a period of 22 months. Again, we did not observe any significant differences neither in body weight nor in urinary albumin excretion ([Figure 5](#fig5){ref-type="fig"}). Histological evaluation revealed no obvious morphological alterations nor did we detect structural mitochondrial defects by TEM ([Figures 5](#fig5){ref-type="fig"}E and 5F). Ultrastructure of podocyte foot processes remained intact ([Figure 5](#fig5){ref-type="fig"}F). Functionally, *Pgc-1α* deletion reduced the mtDNA content in mouse glomeruli with regard to *Atp6* levels, suggesting reduced mitochondrial biogenesis ([Figure S3](#mmc1){ref-type="supplementary-material"}A). However, GC-MS profiling of kidney cortex of mice with podocyte-specific deletion of *Pgc-1α* and respective controls revealed only minor changes in overall metabolite content. Accordingly, lactate levels did not differ between the genotypes ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Knockdown of *Pgc-1α* in human podocytes significantly reduced mitochondrial function and increased glycolysis and glycolytic capacity ([Figures S3](#mmc1){ref-type="supplementary-material"}C--S3G), thereby demonstrating the impact of *Pgc-1α* on mitochondrial biogenesis in podocytes and anaerobic glycolysis as a "back up" pathway to cover podocyte's energy demands. Depletion of PGC-1α did not impact mitochondrial substrate preference, as seen by maintained high levels fatty acid dependency and capacity ([Figures S3](#mmc1){ref-type="supplementary-material"}H--S3O).Figure 5Podocyte-Specific *Pgc-1*α Knockout Mice Are Viable and Do Not Display a Glomerular Phenotype(A) Schematic illustrating targeted gene deletion approach of *Pgc-1α* in podocytes using the Cre-loxP system.(B) After isolation of podocytes via antibody-based labeling followed by FACS, DNA was prepared and respective genotypes were verified using the following primers: *Pgc-1α* WT: forward 5′-ACCTGTCTTTGCCTATGATTC-3′, reverse CCAGTTTCTTCATTGGTGTG; *Pgc-1α* KO forward 5′-TCCAGTAGGCAGAGATTTATGAC-3′, reverse 5′-CCAACTGTCTATAATTCCAGTTC-3′.(C) In a 22-month follow-up period, no differences in body weight were detected between wild-type and *Pgc-1α* knockout animals (at least 3 animals per genotype and time point were analyzed; mean ± SD).(D) Measurement of ACR revealed no differences during the 22-month follow-up period (at least 3 animals per genotype and time point were analyzed; mean ± SD).(E) PAS-stained kidney sections from 3-month-old and 22-month-old *Pgc-1α*^*flox/flox*∗^*hNPHS2Cre* mice and littermate controls showed normal glomerular structure.(F) TEM images obtained from 22-month-old *Pgc-1α*^*flox/flox*^*^∗^hNPHS2Cre* and littermate controls show normal foot process formation and no difference in mitochondrial shape (representative pictures).

Loss of Mitochondrial Transcription and Lack of the OXPHOS Machinery Does Not Result in Podocyte Disease {#sec2.4}
--------------------------------------------------------------------------------------------------------

Furthermore, we studied podocyte-specific *Tfam* knockout mice in order to provide additional *in vivo* evidence and to test the hypothesis that podocytes do not rely on the mitochondrial OXPHOS machinery. We followed knockout and wild-type animals for a period of 12 months and assessed renal function and proteinuria. As shown for *Drp1* and *Pgc-1α* podocyte-specific knockout mice, again, we did not observe any significant differences neither in body weight nor in urinary albumin excretion ([Figure 6](#fig6){ref-type="fig"}). Histological evaluation revealed no obvious morphological alterations ([Figure 6](#fig6){ref-type="fig"}H). Additional TEM studies in 20- and 55-week-old animals revealed a regular slit diaphragm structure ([Figure S4](#mmc1){ref-type="supplementary-material"}A) and no major structural abnormalities in mitochondrial morphology or number ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C). However, *Tfam* depletion significantly reduced mtDNA content in *ex vivo* isolated glomeruli ([Figure S5](#mmc1){ref-type="supplementary-material"}A) and showed the strongest impact on overall metabolite composition as seen in the principal-component analysis ([Figure S5](#mmc1){ref-type="supplementary-material"}B) compared to the other knockout models. In particular, lactate levels significantly increased if TFAM is lacking. Transient knockdown of *Tfam* in human podocytes (as demonstrated in [Figure S5](#mmc1){ref-type="supplementary-material"}C) significantly reduced mitochondrial respiration and respiratory capacity ([Figures S5](#mmc1){ref-type="supplementary-material"}D and S5E). Glycolysis and glycolytic capacity significantly increased ([Figures S5](#mmc1){ref-type="supplementary-material"}F and S5G). As seen in *Drp1* and *Pgc-1α* knockdown experiments, fatty acids remain the main fuel for podocyte OXPHOS *in vitro* ([Figures S5](#mmc1){ref-type="supplementary-material"}H--S5O).Figure 6Podocyte-Specific *Tfam* Knockout Mice Do Not Develop Glomerular Disease(A) Schematic illustrating targeted gene deletion approach of *Tfam* in podocytes using the Cre-loxP system.(B) After isolation of glomeruli, DNA was prepared and respective genotypes were verified using following primers: *Tfam* forward 5′-CTGCCTTCCTAGCCCGG-3′; *Tfam* reverse 1 5′-GTAACAGCAGACAACTTGTG-3′; *Tfam* reverse 2 5′-CTCTGAAGCACATGGTCAAT-3′.(C) Immunofluorescence staining for TFAM in kidney sections obtained from 3-month-old *Tfam*^*flox/flox*^*^∗^hNPHS2Cre* mice and respective controls.(D) 12-month follow-up period revealed no differences in body weight between wild-type, *Tfam*^*flox/+*^*^∗^hNPHS2Cre* mice and *Tfam*^*flox/flox*^*^∗^hNPHS2Cre* mice (at least 3 animals per genotype and time point were analyzed; mean ± SD).(E) Urinary protein excretion was absent during a 12-month follow-up period in *Tfam*^*flox/flox*^*, Tfam*^*flox/+*^*^∗^hNPHS2Cre* mice and *Tfam*^*flox/flox*^*^∗^hNPHS2Cre*, respectively, as indicated by representative Coomassie brilliant blue staining.(F) Serum creatinine levels in 6-month-old *Tfam*^*flox/flox*^*, Tfam*^*flox/+*^*^∗^hNPHS2Cre* mice and *Tfam*^*flox/flox*^*^∗^hNPHS2Cre* mice, respectively (n = 4 each genotype; mean ± SD).(G) Serum urea levels in 6-month-old *Tfam*^*flox/flox*^*, Tfam*^*flox/+*^*^∗^hNPHS2Cre* mice and *Tfam*^*flox/flox*^*^∗^hNPHS2Cre* mice, respectively (n = 4 each genotype; mean ± SD).(H) PAS-stained kidney sections obtained from 55-week-old *Tfam*^*flox/flox*^*, Tfam*^*flox/+*^*^∗^hNPHS2Cre* mice and *Tfam*^*flox/flox*^*^∗^hNPHS2Cre* mice, respectively.(I) Glomerulosclerosis assessment in kidney sections obtained from 55-week-old *Tfam*^*flox/flox*^ and *Tfam*^*flox/flox*^*^∗^hNPHS2Cre* mice, as proposed by [@bib16]. Adriamycin-induced nephropathy in WT mice (ICR-CD1 background sacrificed 50 days after induction) served as positive control (n = 3 each group; 100 glomeruli were assessed per mouse; mean ± SD).

Because knockdown of *Tfam* by using siRNA did not allow for complete abrogation of the protein, we aimed to further validate our findings by isolating primary podocytes after additional matings of *Tfam* podocyte knockout mice with a fluorescent reporter mouse ([Figure 7](#fig7){ref-type="fig"}A). Surprisingly, we did not observe any clear morphologic effect on the mitochondrial network ([Figure 7](#fig7){ref-type="fig"}B). However, as a result of the decrease in TFAM, we observed a differential regulation of proteins of the respiratory chain. Protein expression of mitochondrial-encoded genes, such as mtNdufb8, mtCO1, and ATP5A, were strongly decreased, reflecting an abrogated mitochondrial transcription and a strong reduction of complex I, IV, and V of the respiratory chain. The level of ubiquinol-cytochrome C reductase (UQCR) of complex III was only slightly reduced. By contrast, we did observe a strong reduction in the succinate dehydrogenase (ubiquinone) iron-sulfur subunit (SDHB) of complex II in the absence of TFAM, which is primarily nuclear encoded ([Figure 7](#fig7){ref-type="fig"}C). OCR of *Tfam* knockout podocytes was strongly reduced, indicating severe abrogation of OXPHOS as intended ([Figures 7](#fig7){ref-type="fig"}D and 7E). Severe mitochondrial dysfunction was associated with strongly reduced reactive oxygen species (ROS) production as observed in *Tfam* knockout podocytes compared to wild-type (WT) and heterozygous *Tfam* deletion ([Figure 7](#fig7){ref-type="fig"}F). Surprisingly, anaerobic glycolysis and glycolytic capacity decreased as well *in vitro* ([Figures 7](#fig7){ref-type="fig"}G and 7H), however, still allowing for maintained podocyte ATP supply, as indicated by podocyte integrity *in vivo*. In summary, compared to the other knockout models in this study, deletion of *Tfam* showed the strongest impact on mitochondrial function and podocyte metabolism *in vivo* and *in vitro*. Neither *Drp1* nor *Pgc-1α* or *Tfam* deletion was able to induce phenotypic abnormalities in podocytes *in vivo*. Accordingly, GC-MS profiling revealed only slight and distinct metabolic changes in *ex vivo* isolated kidney cortex of these mice ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B), suggesting a functionally fully compensated metabolic state due to increased anaerobic glycolysis in these models if mitochondria become genetically targeted.Figure 7Metabolic Profiling of *Tfam*-Deficient Podocytes Revealed Decreased Respiratory Activity(A) Schematic illustrating breeding strategy to generate primary podocytes lacking *Tfam*.(B) Immunofluorescence image obtained from primary podocytes deficient for *Tfam* and controls shows a comparable distribution and intensity for the mitochondrial marker TOMM20 (red).(C) Western blot analysis for key components of the respiratory chain revealed lower levels of MTCO1 in *Tfam*-deficient podocytes (n = 4; ^∗^p ≤ 0.05; mean ± SD).(D) OCR from *Tfam*-deficient podocytes and controls at baseline and after subsequent injection of oligomycin, FCCP, and rotenone, antimycin A (mean ± SD). Final concentration: oligomycin: 1 μM; FCCP: 0.5 μM; rotenone: 0.5 μM; antimycin: 0.5 μM.(E) Statistics of key parameters of respiratory function in *Tfam*-deficient podocytes and controls (^∗^p ≤ 0.05; ^∗∗^p ≤ 0.01; mean ± SD).(F) Quantitative CM-H2DCFDA fluorescence obtained from primary podocytes with complete or heterozygous disruption of *Tfam* and controls, indicating oxidative stress (^∗∗^p ≤ 0.01; ^∗∗∗^p ≤ 0.001; mean ± SD).(G) Extracellular acidification rate of *Tfam*-deficient podocytes and respective controls followed after glucose administration and subsequent injection of oligomycin and 2-DG (mean ± SD). Final concentration: glucose: 10 mM; oligomycin: 1 μM; 2-DG: 50 mM.(H) Statistics of key parameters of glycolytic activity obtained from *Tfam*-deficient podocytes and respective controls (^∗^p ≤ 0.05; ^∗∗^p ≤ 0.01; mean ± SD).

Discussion {#sec3}
==========

Mitochondria are semi-autonomous organelles, the "cell's power plants," that produce the most of its ATP supply via the OXPHOS. Beyond energy supply, they are involved in crucial pathways for homeostasis, phagocytosis, and apoptosis. Mitochondria are also recognized as an important signaling platform that utilizes molecules like ADP and ATP, Ca^2+^, respiratory chain metabolites, ROS, or the unfolded protein response to regulate cross-communication with other organelles and the nucleus (reviewed in [@bib41]). Preservation and fitness of this crosstalk, under physiological or stress conditions, is necessary for normal cell function and homeostasis and alterations often result in pathological phenotypes. However, the regulatory mechanisms of this vital communication between the cell compartments in states of health and disease remain unclear. Mitochondrial genome regulation as well as the organelles distribution into the cell---specified by balanced fission and fusion---must be in accordance to tissue-dependent cellular needs. Respiratory activity of each tissue type determines the energetic threshold under which mitochondrial impairment leads to a disease phenotype. Although, so far, mitochondrial diseases were assigned to OXPHOS impairment, during the last years there are accumulating data supporting that impairment of mitochondria signaling can lead to disease independently of the energy production levels ([@bib42]).

It is the matter of a long-standing debate to what extent the resident cells of the glomerulus, and in particular the podocytes, contribute actively to the filtering process. Glomeruli are thought to filter the plasma continuously, but filtration rates vary strongly dependent on physiological regulation, nephron type, and metabolic activity ([@bib47]). There is, however, a general consensus that podocytes are essential for the buildup of the glomerular filtration barrier as they orchestrate glomerular endothelial cell functions through secreted vascular endothelial growth factor (VEGF; reviewed in [@bib4]) and maintain the structural and functional integrity of the glomerular basement membrane (reviewed in [@bib31]). Moreover, the fact that GBM and slit diaphragm component synthesis occurs in podocytes reveals their crucial role in maintaining the kidney filtration barrier, as well as their involvement in glomerular disease development. Podocytes represent the outer layer of the vascular filter counterbalancing mechanic forces as the result of a pulsatile blood flow. Hence, it is not surprising that podocytes harbor an actin-based cytoskeleton, including a contractile machinery allowing rapid shape remodeling and podocyte movement ([@bib38]). Podocytes fine-structure and function maintenance implies metabolic activity, but so far their detailed metabolic profile remains obscure (reviewed in [@bib22]). In 2010, Abe and colleagues provided first experimental evidence for a critical role of mitochondria and, in particular, a high dependency of podocytes on mitochondrial energy delivery using an immortalized podocyte cell line ([@bib1]). Inhibition of glycolysis or oxidative phosphorylation each reduced ATP levels and were thought to explain the susceptibility of podocytes to oxidative stress as observed in patients with diabetic nephropathy. On the contrary, [@bib37] suggested that both glycolytic and OXPHOS pathways contribute to podocyte energy supplements, depending on the intracellular sub-localization of mitochondria and on the cell differentiation status. [@bib23] recorded that high-glucose conditions forced differentiating human podocyte cell lines to switch from OXPHOS to glycolysis, resulting in lactic acidosis. Here, we provide comprehensive metabolomics data from freshly isolated glomeruli and primary podocytes as well as the results from three independent mouse models highlighting the podocytes' independence from mitochondrial energy sources. In contrast, we observed, both *in vitro* and *in vivo*, a strong dependency on cytosolic degradation of glucose to lactate. Neither impaired mitochondrial biogenesis nor defective fission machinery nor mitochondrial transcription resulted in podocyte dysfunction. These experimental findings challenge our view on the mitochondrial contribution to podocyte function and the metabolic status of podocytes in general. Primarily, podocytes do not rely on mitochondrial energy sources under physiological conditions but rather metabolize glucose to lactate instead to meet their energy needs---very similar to Warburg's hypothesis for cancer cells and many *in vitro* cell culture systems. Podocytes are terminally differentiated quiescent cells. There is accumulating evidence that quiescence is accompanied with strong metabolic changes in order to ensure the maintenance of the cell's proper function and survival. This metabolic switch from mitochondrial respiration to glycolysis or vice versa is not uniform but rather depends on the cell type and cell environmental context (reviewed in [@bib48]). For instance, hematopoietic cells dependence on glycolysis for energy production is related to their localization in a hypoxic niche in the bone marrow ([@bib46]). Nephron progenitors' localization in hypoxic niche also appears to be strongly related to glomerulogenesis through HIF-1a and HIF-2a possible interaction with VEGF (reviewed in [@bib20]).

We hypothesize that podocytes counteract cellular acidification due to the accumulation of lactate by secretion into the primary urine surrounding the podocytes' cell bodies. The most convincing evidence to support our hypothesis and the independence of podocytes from mitochondrial ATP production comes from clinical observations. Acute kidney injury (AKI) is defined as progressive loss of renal function within hours and often occurs due to a sudden decrease in renal blood flow, leading to kidney ischemia. Patients suffering from AKI usually present with elevated blood urea nitrogen and creatinine levels and a reduction in urine output. Rarely, increased levels of albuminuria are observed, excluding a significant contribution of the glomerular filtration barrier to the course of disease.

Based on our experimental data, we now speculate that not the loss of mitochondrial OXPHOS is detrimental for podocyte function and, eventually, survival but rather a change in podocyte metabolism. The impact of *Drp1*, *Pgc-1α*, or *Tfam* depletion on mitochondrial function and podocyte metabolism was only minor, with the strongest changes in overall metabolite content toward increased anaerobic glycolysis being observed in the TFAM-deficient podocytes. Overall, these observations suggest a fully compensated metabolic state due to increased anaerobic glycolysis in these models if mitochondria become genetically targeted.

In the light of recent data, we speculate that mitochondria are critical regulators of metabolic signaling events in podocytes, with mTOR being the ultimate cellular effector kinase ([@bib17], [@bib19]). Mice with a genetic ablation of prohibitin-2, a scaffold protein in the inner mitochondrial membrane that does not affect the OXPHOS machinery, displayed a severe glomerular disease phenotype and premature death after 4 or 5 weeks, which could be ameliorated by interfering with the insulin-signaling cascade and its downstream mediator mTOR ([@bib24]). Similarly, a transgenic mouse model with genetic activation of mTOR resulted in increased metabolic signaling and the onset of FSGS ([@bib58]). Notably, the knockout of mTORC1 by induced deletion of both *Raptor* alleles was also found to be detrimental and led to an accelerated progression of FSGS. In contrast, lowering mTORC1 activity by genetic depletion of one *Raptor* allele ameliorated the progression of glomerulosclerosis in various disease models ([@bib18], [@bib58]). Taken together, these findings lead to the hypothesis that mTOR serves as key regulator of podocyte metabolism without affecting the preferences for the used metabolic pathways. We did not observe a compensatory upregulation of the mitochondrial OXPHOS machinery in the absence of neither *Pgc-1α* nor *Drp1*. We can only speculate on the observed decrease in glycolysis in *Tfam* knockout (KO) podocytes. This effect could reflect the reduced CO2 emission by the OXPHOS machinery---also it contributes only very little to the overall ATP content. However, it could also be secondary to the cell isolation protocol, which may result in cellular stress---a condition during which the mitochondrial OXPHOS machinery is required to ascertain cellular function and survival, even though we did not observe an increased rate of cell death in the *Tfam* knockout cells as compared to the control cells. The metabolic framework characterized in this study primarily reflects podocyte metabolism under physiological, non-stressed conditions. It provides an experimental basis to extend our understanding on the mitochondrial contribution to podocyte diseases. The independence of mitochondrial ATP production under physiological conditions not only represents a functional reserve in post-mitotic podocytes but furthermore serves as intracellular source for increased amounts of reactive oxygen species and thereby, ultimately, increased cellular damage and podocyte loss as reported for diabetic nephropathy as a result of hyperglycemia ([@bib2], [@bib9], [@bib14], [@bib28]). Along these lines, Qi and colleagues reported in 2017 ([@bib40]) a differential upregulation of enzymes in the glycolytic, sorbitol, methylglyoxal, and mitochondrial pathways to be protective in the setting of diabetic kidney disease. In particular, activation of PKM2 was shown to be protective against diabetic nephropathy (DN) by increasing glucose metabolic flux, inhibiting the production of toxic glucose metabolites and inducing mitochondrial biogenesis to restore mitochondrial function. Hence, a differential and well-orchestrated regulation of multiple signal pathways is required to overcome the deleterious effects of increased mitochondrial ROS, which is distinct from the basal independence of podocytes on the mitochondrial ATP, content. Interfering with the production or scavenging of ROS might represent suitable therapeutic strategies to treat patients with DN ([@bib5]). Activation of the Nrf2/Keap1 pathway by small molecules may serve as one example currently undergoing extensive clinical testing ([@bib10]). There is additional, mostly circumstantial data from *in vitro* and *in vivo* models, suggesting a contribution of OXPHOS pathways to the development of podocyte disease. In particular, increased activity of PGC-1α and, as a result, increased mitochondrial biogenesis has been reported to contribute to the development of collapsing glomerulopathy ([@bib29]), and it appeared to be protective in a model of aldosterone-induced podocyte injury ([@bib57]). Hyperglycemia itself has been reported to activate podocyte metabolism by inducing DRP1-mediated mitochondrial fission through ROCK1 ([@bib53]). As it relates to TFAM and the role of mtDNA stability and mtDNA transcription, very little is known about its importance for kidney cells although global deletion of *Tfam* was embryonically lethal ([@bib27]). Kidneys from heterozygous *Tfam*^+/−^ mice present with mtDNA depletion that is not followed by OXPHOS deficiency ([@bib27]) Moreover, TFAM overexpression in mice leads to mtDNA copy number increase in all tissues---including kidney---without affecting mtDNA expression and OXPHOS function ([@bib15]). Conditional disruption of *Tfam* expression in heart and skeletal muscle cells resulted in a severe phenotype and death of the animals after 2--4 weeks of age ([@bib52]), although loss of TFAM in epidermal progenitor/stem cells (EPSCs) had no effect on epidermal development and skin barrier function ([@bib3]), very similar to the lack of any disease phenotype as reported for podocytes in this study. Differential regulation of the different complexes of the OXPHOS machinery in the absence of TFAM, including the nuclear-encoded genes of complex II as observed in this study and also by [@bib49] in brown adipose tissue, may contribute to the tissue-specific consequences of a targeted *Tfam* deletion, ranging from the absence of any phenotype to embryonic lethality.

In conclusion, this study provides insights into podocyte metabolism as podocytes primarily rely on anaerobic glycolysis and only to a minor extent on β-oxidation of lipids. Overall, mitochondrial oxidative phosphorylation has only very limited impact on the overall podocyte ATP synthesis. As such, anaerobic glycolysis and the fermentation of glucose to lactate is the predominant metabolic pathway of podocytes and therefore represents a key target for therapeutic interventions in glomerular disease with enhanced metabolism, such as diabetic nephropathy.
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REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**anti-podocinSigmaP0372anti-TOMM20Santa Cruzsc-11415anti-TFAMSanta Cruzsc-23588anti-DRP1BD Transduction611112anti-NEPHRINProgenGP-N2anti-SYNAPTOPODINSynapotic Systems163 004anti-PKM2Cell SignalingD78A4anti-SOD2Acris AntibodiesAPO3023PU-Santi-alpha TUBULINSigmaT6199anti-PGC-1aMerck Milipore4C1.3OXPHOS Rodent WB Antibody CocktailAbcamAb110413anti-ATPAbcamAB113849**Bacterial and Virus StrainsChemicals, Peptides, and Recombinant Proteins**CM-H2DCFDAInvitrogenC6827oligomycinSigma75351FCCPSigmaC2920antimycin ASigmaA8674rotenoneAbcamAb14315etomoxirSigmaE1905BPTESSigmaSML0601UK5099SigmaPZ01602-DGSigmaD6134oxamateSigmaO2751**Critical Commercial Assays**Seahorse XFp Mito Fluel Flex TestAgilent TechnologiesN/AMito Stress TestAgilent TechnologiesN/ASeahorse XF Glycolysis Stress Test KitAgilent TechnologiesN/A**Experimental Models: Cell Lines**Immortalized human podocytes[@bib43]N/A**Experimental Models: Organisms/Strains**B6.129S4(FVB)-Ppargc1atm1Brsp/J[@bib30]N/AB6.Drp1flox/flox/J[@bib51]N/AB6.Tfamflox/flox/N[@bib27]N/AB6.hNPHS2Cre[@bib32]N/AGt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/JJackson LaboratoryN/A**Oligonucleotides**Tfam forward 5′-CTGCCTTCCTAGCCCGG-3′[@bib27]N/ATfam reverse 1 5′-GTAACAGCAGACAACTTGTG-3′[@bib27]N/ATfam reverse 2 5′-CTCTGAAGCACATGGTCAAT-3′[@bib27]N/APgc-1α WT: frwd 5′-ACCTGTCTTTGCCTATGATTC[@bib30]N/APgc-1α WT: reverse 5′- CCAGTTTCTTCATTGGTGTG −3′[@bib30]N/APgc-1α KO forward: 5′-TCCAGTA GGCAGAGATTTATGAC-3′[@bib30]N/APgc-1α KO reverse: 5′-CCAACTGTCTATAATTCCAGTTC-3[@bib30]N/ADrp1: D1 5′-CACTGAGAGCTCTATATGTAGGC-3′[@bib51]N/AD3 5′-ACCAAAGTAAGGAAT AGCTGTTG-3′[@bib51]N/AD5 5′-GAGTACCTAAAGTGGACAAGAGGTCC-3′[@bib51]N/Acox1Thermo Fisher ScientificMm04225243_g1Atp6Thermo Fisher ScientificMm03649417_g118SThermo Fisher ScientificHs99999901_s1siRNA Drp1, Pgc1alpha and TfamOn Target Smart Pool, DharmaconN/A**Software and Algorithms**Imaris software v7.6BitplaneN/ALabImage ID softwareKapelan Bio-ImagingN/ASeahorse XFp software version 2.2.0Seahorse BioscienceN/AGraphPad Prism Version 6GraphPad SoftwareN/AMetaboAnalyst[@bib55]N/A
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Tobias B. Huber (<t.huber@uke.de>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Animals {#sec4.3.1}

Mice: B6.129S4(FVB)-Ppargc1a^tm1Brsp^/J were a generous gift from B. Spiegelman ([@bib30]). *Drp1*^flox/flox^ mice ([@bib51]) on C57BL/6J background were a generous gift from H. Sesaki (Johns Hopkins University School of Medicine, Baltimore). *Tfam*^flox/flox^ mice ([@bib27]) on C57BL/6N background were a generous gift from N.G. Larsson (Max Planck Institute for Biology of Aging, Cologne/Germany). All mice were backcrossed to pure C57BL/6J or 6N background, respectively. To obtain a podocyte-specific knockout of *Drp1*, *Tfam* and *Pgc-1α*, respectively, mice harboring the respective floxed allele were further crossed to *hNPHS2Cre* mice provided by L. Holzman (Renal, Electrolyte and Hypertension Division, University of Pennsylvania School of Medicine, Philadelphia, PA, USA) to generate a podocyte specific knockout. Only male mice were phenotypically analyzed (cohort size: *Drp1*: n = 10; *Pgc-1α*: n = 6, *Tfam:* n = 8; control cohorts (WT) include 10, 6 and 8 mice, respectively). Male *hNPHS2Cre* negative littermates served as controls. All animal experiments were conducted according to the guidelines of the Committee on Research Animal Care and the German and Swiss law for the welfare of animals. All experiments were approved by local authorities (Regierungspraesidium Freiburg (G11/38, G14/45), Kantonales Veterinäramt of the Kanton Basel and the LANUV NRW (State Agency for Nature, Environment and Consumer Protection North Rhine-Westphalia), respectively. Mice had free access to chow and water and a 12-hour day/night cycle. Breeding and genotyping was done according to standard procedures. To isolate primary podocytes *Tfam*^*flox*/flox∗^*hNPHS2Cre*^+^ were crossed to *Tomato/eGFP* reporter mice. Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J mice were purchased from Jackson Laboratory (Bar Harbor, ME). *Tfam*^flox/flox^; *Tomato/eGFP*^∗^*hNPHS2Cre*^+^ and *WT;Tomato/eGFP*^∗^*hNPHS2Cre*^+^ were chosen for primary cell isolation.

### Primary Cell Culture {#sec4.3.2}

Isolation of primary podocytes was performed as recently described ([@bib44]). In brief glomeruli from 2 week old *Tfam*^flox/flox^*;Tomato/eGFP;hNPHS2Cre*^+^ and *WT;Tomato/eGFP;hNPHS2Cre*^+^ mice, respectively, were isolated by sieving. After culture of 5 days FACS procedure was performed to isolate the GFP-positive population of primary podocytes. For all *ex vivo* experiments podocytes were kept in 5.5mM D-glucose reflecting normoglycemic conditions.

Method Details {#sec4.4}
--------------

### Urine and serum analysis {#sec4.4.1}

Urinary albumin was analyzed with Coomassie gel stains and measured using a fluorimetric albumin test kit (Progen, PR2005). Urinary creatinine was measured using enzymatic colorimetric creatinine kit (Labor+Technik, LT-CR0053) as described in the manufacturer's instructions.

### Histology and electron microscopy {#sec4.4.2}

Kidneys were fixed in 4% paraformaldehyde and embedded in paraffin and further processed for PAS and HE staining. For quantitative assessment of glomerular lesions as previously described by El Nahas ([@bib16]) 2 μm PAS stained kidney slides of at least 3 animals were analyzed for focal (1 point) or total sclerosis (2 points). The sum was divided by the number of counted glomeruli. This was done in a blinded fashion and repeated by a second renal pathology experienced scientist.

For transmission electron microscopy, tissue blocks were washed after post fixation in 0.1M PB, and sections (thickness: 50 μm) of the kidney were cut by using vibratome. After incubation in 1% OsO4, the sections were stained with uranyl acetate, dehydrated and flat embedded in epoxy resin (Durcupan ACM, Fluka, Sigma-Aldrich, Gillingham, UK). 40 nm ultrathin sections were cut and analyzed using an 80kV Zeiss Leo transmission electron microscope.

### *Ex vivo* podocyte isolation and DNA isolation and PCR {#sec4.4.3}

To confirm the podocyte-specific knock out of *Tfam*, *Pgc-1α* and *Drp1*, respectively, podocytes were *ex vivo* isolated after Dynabead perfusion and several digestion steps. Finally, podocytes were captured by anti-podocin antibody (P0372, Sigma) coupled to Alexa Fluor 488 (Z25302, Thermo Scientific) (*Pgc-1α*) or isolated due to their GFP-signal (*Tfam*^*flox/flox*^*;Tomato/eGFP;hNPHS2Cre*^+^ and *Drp1*^*flox/flox*^;*Tomato/eGFP;hNPHS2Cre*^*+*^ mice). DNA was isolated using DNeasy kit (QIAGEN, 69504) following manufacturer\`s instructions. PRC was performed using following primers: *Tfam* forward 5′-CTGCCTTCCTAGCCCGG-3′, *Tfam* reverse 1 5′-GTAACAGCAGACAACTTGTG-3′, *Tfam* reverse 2 5′-CTCTGAAGCACATGGTCAAT-3′. *Pgc-1α* alpha primer: *Pgc-1α* WT: frwd 5′-ACCTGTCTTTGCCTATGATTC, reverse 5′- CCAGTTTCTTCATTGGTGTG −3′; *Pgc-1α* KO forward: 5′-TCCAGTA

GGCAGAGATTTATGAC-3′, reverse: 5′-CCAACTGTCTATAATTCCAGTTC-3′.

*Drp1*: D1 (5′-CACTGAGAGCTCTATATGTAGGC-3′), D3 (5′-ACCAAAGTAAGGAAT

AGCTGTTG-3′) and D5 (5′-GAGTACCTAAAGTGGACAAGAGGTCC-3′).

### Staining of podocytes and ROS detection {#sec4.4.4}

Primary podocytes obtained from *Tfam*^flox/flox^;*Tomato/eGFP;hNPHS-Cre*^+^ and *WT; Tomato/eGFP;hNPHS2Cre*^*+*^ mice were seeded on collagen coated coverslips. 24h later cells were fixed with paraformaldehyde (4% in phosphate buffered saline (PBS)) and stained with rabbit anti TOMM20 (Santa Cruz, sc-11415).

For ROS detection primary podocytes were seeded in a 96 well plate with clear flat bottom and black sides the day before the experiment (25 000 cells/well). After washing podocytes were incubated in 5 μM working solution of CM-H2DCFDA (Invitrogen, C6827) at 37°C in the dark. CM-H2DCFDA was replaced by PBS and excitation/emission was measured (485/535nm) in a plate reader (Tecan Infinite).

### Immunofluorescence staining {#sec4.4.5}

*Tfam*^*flox/flox*^*^∗^hNPHS2Cre* and *Drp1*^*flox/flox*^*^∗^hNPHS2Cre* and respective controls were perfused with phosphate buffered saline (PBS) via cardiac perfusion. For TFAM staining mice kidneys were fixed in 4% formaldehyde, embedded in paraffin and cut in 4 μm sections. Samples were deparaffinized in xylene and rehydrated in ethanol gradient (100% - 95% - 70%). The slides were washed with TBST (Tris-buffered-saline with 0.025% Tween 20) and boiled in Tris-EDTA pH 9.0 for 10 min to obtain antigen retrieval. After washing with milliQ water and TBST samples were blocked with 5% BSA and 5% normal donkey serum in TBST for 1 hour at room temperature. Incubation with primary antibodies overnight at 4°C was followed by secondary antibodies for 60 min at room temperature. Following antibodies were used: anti mtTFA (A-17) (Santa Cruz, sc-23588), anti PODOCIN (Sigma, P0372). Imaging was performed with a Leica DMI 6000 B inverted microscope - HCX PL APO 63x/1.40 oil immersion objective. All images were further processed with the CorelDRAW(R) Graphics Suite X6.

For DRP1 staining, kidneys were snap-frozen in cryogenic Tissue-Tek O.C.T. compound (Electron Microscopy Sciences) and 4 μm cryosections were generated with a Leica Kryostat (Leica, Wetzlar, Germany). Sections were fixed with PFA 4%, followed by treatment with NH~4~CL (50 mM) and blocking with 5% BSA in PBS. Subsequently the sections were incubated with following primary antibodies for 60 minutes: anti-DRP1 (BD Transduction) and anti-NEPHRIN (guinea pig, 1:300, Progen) After several rinses, appropriate fluorophore-conjugated Alexa secondary antibodies (Invitrogen) in a final dilution of 1:500 were applied for 30 minutes. Images were taken using a Zeiss fluorescence microscope.

For localization studies of glycolysis (assessed for PKM2 distribution) and mitochondrial distribution (assessed for SOD) indirect immunofluorescence was performed following the protocol described above. Podocytes were identified using synaptopodin (Synaptic Systems; 163 004), glycolytic enzyme abundance was assessed via PKM2 (Cell Signaling Technology D78A4) and mitochondrial distribution was visualized via SOD2 expression (Acris Antibodies; APO3023PU-S). Image acquisition was performed using a scanning confocal microscope (LSM800, Zeiss) with airy scan function, which allowed image post processing. 3D reconstructions, distributions and volumetric calculations (i.e., maximal distance to podocyte nuclei) were performed based on 6 stacks per group by using Imaris software v7.6 (Bitplane).

### Cell and glomerular lysis and western blot procedure {#sec4.4.6}

Glomeruli were isolated by Dynabead perfusion. Cells were harvested by trypsinization and lysis was performed using RIPA buffer. Protein concentration was determined by BCA assay (Pierce Biotechnology, 23225). Equal amounts of protein were separated on SDS-PAGE. Afterward, gels were transferred to a polyvinyl difluoride membrane (iBlot Gel Transfer Stacks, Life Technologies, IB401001) by dry blotting technique (iBlot® 2 Dry Blotting System, Life technologies). Membranes were blocked in 5% PBS-BSA Following antibodies were used for western blot: anti β-ACTIN (Sigma, A9357), anti-alpha TUBULIN (Sigma, T6199), anti DRP-1 (Cell Signaling Technology, D6C7), anti TFAM (Abcam, ab131607), anti PGC-1α (Merck Milipore, 4C1.3), total OXPHOS Rodent WB Antibody Cocktail (Abcam, ab110413). Densitometry was performed using LabImage ID software (Kapelan Bio-Imaging).

### qPCR for mitochondrial and nuclear DNA targets {#sec4.4.7}

DNA was extracted out of *ex vivo* isolated glomeruli (Dynabead perfusion for high purity, 4 mice per genotype at the age of 24 weeks) using the QIAGEN DNeasy Blood & Tissue kit according to the manufacturer's instructions and total concentrations were measured with the Thermo Fisher NanoDrop spectralphotometre. DNA was diluted to 2,5ng/μl and the individual dilution factors were noted down. mtDNA copy numbers were assessed by conducting qPCR, in which 18S was used for measurement of genomic DNA and served as loading control and Rnr2 and cox1 were used for measuring mitochondrial genes (Thermo Fisher Scientific, cox1: Mm04225243_g1; Atp6: Mm03649417_g1; 18S: Hs99999901_s1). Measurements were compared to five standard dilutions, ranging from undiluted to the highest dilution factor used when diluting the DNA isolated out of podocytes. Four technical replicates were measured per sample.

### Seahorse XFp mitochondrial analysis and ATP measurement {#sec4.4.8}

Optimization of cell density for primary podocytes as well as optimization of the working concentration titers for each individual inhibitor was conducted prior to the Seahorse XFp experiments according to the manufacturer\`s instructions (Agilent Technologies). Cells were seeded at a density of 20 000 cells/well. The Seahorse XFp Mito Fluel Flex Test, Mito Stress Test and assessment of glycolytic activity was performed following the manufacturer\`s instruction. Specifically, podocytes on XFp microplates were rinsed. XF assay buffer was added. Afterward the plate was equilibrated for 1 h at 37°C in a non-CO2 incubator. All medium and solutions of mitochondrial complex inhibitors were adjusted to pH 7.4 on the day of assay. Following four baseline measurements of OCR and ECAR, inhibitors of the respiratory chain were sequentially injected into each well. Three OCR and ECAR readings were taken after addition of each inhibitor and before automated injection of the subsequent inhibitor. Mitochondrial complex inhibitors, in order of injection, included oligomycin (1 μM) to inhibit complex V, FCCP (0.5 μM) to uncouple the proton gradient, antimycin A (1.0 μM, inhibitor of complex III), and rotenone (1.0 μM, complex I inhibitor). For Mito Fuel assessment etomoxir, BPTES, UK5099 were used with final concentration of 100 μM (etomoxir) and 30 μM (BPTES, UK5099). OCR and ECAR were automatically calculated by Seahorse XFp software version 2.2.0 (Seahorse Bioscience, Billerica, MA, USA). After each experiment podocytes were fixed with paraformaldehyde and nuclei were stained with DAPI. Olympus ScanR Screening Station for high-throughput microscopy detection (Olympus, Tokyo, Japan) was used for assessment of cell number to normalize XFp analysis data.

Knock-down experiments for *Drp1*, *Pgc-1α* and *Tfam*, respectively, were performed in immortalized human podocytes (kindly provided by Moin Saleem (Bristol, UK)) ([@bib43]). Podocytes were seeded in RPMI 1640 supplemented with 10% FCS, Insulin/Transferrin/Selenite, Penicillin/Streptomycin (all from Roche Diagnostics, Mannheim, Germany), Pyruvate, 100x Minimal Essential Medium and HEPES Buffer (all Life technologies, Darmstadt, Germany). When cells had grown to 60% confluence differentiation was induced at 37.0°C for 10--14 days. Cultured human podocytes were fully differentiated before any experiment.

Knock-down experiments for *Drp1*, *Pgc-1α* and *Tfam*, respectively, were performed by using predesigned pooled siRNA (four targeting one gene, On target SMART pool, Dharmacon). Transfection was performed by using electroporation (Amaxa nucleofector technology, Lonza) according to manufacturer's instructions. Efficiency of the knockdown was confirmed 48 hours after transfection using western blot. The Seahorse XFp Mito Fluel Flex Test, Mito Stress Test and assessment of glycolytic activity was performed 48h after transfection.

For ATP measurement primary podocytes were treated with 2-DG (50 mM), oxamate (45 mM), etomoxir (100 μM) and oligomycin (1μM) and ATP measurement was performed using luminescent ATP detection (Abcam 113849) following the manufacturer\`s instructions.

### GC/MS based untargeted metabolomics screen {#sec4.4.9}

Glomeruli were *ex vivo* harvested using Dynabead perfusion. Tubular compartment was isolated by microdissection. To assess the impact of *Drp1*, *Pgc-1α* and *Tfam* deletion, respectively, on metabolite profiles, kidney cortex obtained from 24-week-old mice from each genotype and respective controls were analyzed (n = 4 each). All tissue preparation was performed on ice in less than 30 s. Metabolites were extracted in 90% methanol and 10% water at −20°C containing 1 μg/ml ribitol and 1 μg/ml phenylglucose as internal standards. Tissue lysis was performed by using a Precellys 24 homogenizer with screw cap vials prefilled with 300 mg glass beads (diameter 600 μm) as follows: two times three cycles of 30 s homogenization and 30 s break at −20°C. Further sample processing and metabolic profiling was conducted as described by [@bib54]. In summary, after centrifugation, metabolite containing supernatant was dried overnight and the pellet was derivatized by methoxyamination and silylation. Untargeted GC/MS profiling was performed with a 30 m HP5-MS column coupled to an electron impact mass spectrometer. Features were deconvoluted, aligned and annotated according to mass spectral similarity and retention index of three different libraries. The principal component analysis (PCA) and heatmap were generated by MetaboAnalyst ([@bib55]).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Statistical analysis {#sec4.5.1}

Results of all experiments are presented as mean ± SD. To test for statistical significance of observed effects two-tailed t test was used calculated with GraphPad Prism (Version 6, GraphPad Software, La Jolla, California, USA). p value ≤ 0.05 represented statistically significant differences.
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